137 related articles for article (PubMed ID: 11900516)
21. Hepatocellular injury in a patient receiving rosiglitazone. A case report.
Al-Salman J; Arjomand H; Kemp DG; Mittal M
Ann Intern Med; 2000 Jan; 132(2):121-4. PubMed ID: 10644273
[TBL] [Abstract][Full Text] [Related]
22. Late-onset troglitazone-induced hepatic dysfunction.
Bell DS; Ovalle F
Diabetes Care; 2000 Jan; 23(1):128-9. PubMed ID: 10857986
[No Abstract] [Full Text] [Related]
23. Lessons from the glitazones: a story of drug development.
Gale EA
Lancet; 2001 Jun; 357(9271):1870-5. PubMed ID: 11410214
[TBL] [Abstract][Full Text] [Related]
24. Rosiglitazone toxicity.
Ravinuthala RS; Nori U
Ann Intern Med; 2000 Oct; 133(8):658. PubMed ID: 11033603
[No Abstract] [Full Text] [Related]
25. 'Intrahepatic cholestatic hepatitis following diagnostic ajmaline challenge'.
Mellor G; Fellows I; Williams I
Europace; 2013 Mar; 15(3):314. PubMed ID: 22804909
[No Abstract] [Full Text] [Related]
26. Commentary on 'Case series of liver failure associated with rosiglitazone and pioglitazone' by Floyd et al.
Osei SY; Koro CE; Cobitz AR; Kolatkar NS; Stender M
Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1244-6. PubMed ID: 19655316
[No Abstract] [Full Text] [Related]
27. Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis.
Lenhard MJ; Funk WB
Diabetes Care; 2001 Jan; 24(1):168-9. PubMed ID: 11194222
[No Abstract] [Full Text] [Related]
28. Glibenclamide-induced cholestasis.
Tholakanahalli VN; Potti A; Heyworth MF
West J Med; 1998 Apr; 168(4):274-7. PubMed ID: 9584675
[No Abstract] [Full Text] [Related]
29. Commentary on 'Case series of liver failure associated with rosiglitazone and pioglitazone' by James Floyd et al.
Beiderbeck AB; Sakaguchi M
Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1247-9. PubMed ID: 19842093
[No Abstract] [Full Text] [Related]
30. Thiazolidinediones in diabetes: current status and future outlook.
Camp HS
Curr Opin Investig Drugs; 2003 Apr; 4(4):406-11. PubMed ID: 12808879
[TBL] [Abstract][Full Text] [Related]
31. Actos (pioglitazone HCL) provides a safe, effective alternative for patients formerly taking Rezulin.
Diabetes Technol Ther; 2000; 2(2):290-1. PubMed ID: 11469274
[No Abstract] [Full Text] [Related]
32. Pioglitazone-associated fulminant hepatic failure.
Chase MP; Yarze JC
Am J Gastroenterol; 2002 Feb; 97(2):502-3. PubMed ID: 11866308
[No Abstract] [Full Text] [Related]
33. Thiazolidinedione hepatotoxicity: a class effect?
Tolman KG
Int J Clin Pract Suppl; 2000 Oct; (113):29-34. PubMed ID: 11965828
[TBL] [Abstract][Full Text] [Related]
34. Correction: Liver injury and rosiglitazone.
Ann Intern Med; 2000 Aug; 133(3):237. PubMed ID: 10906846
[No Abstract] [Full Text] [Related]
35. Pioglitazone (Actos).
Med Lett Drugs Ther; 1999 Nov; 41(1066):112. PubMed ID: 10987011
[No Abstract] [Full Text] [Related]
36. Erythromycin-associated cholestatic hepatitis and liver dysfunction in children: the British experience.
Karthik SV; Casson D
J Clin Gastroenterol; 2005 Sep; 39(8):743-4. PubMed ID: 16082288
[No Abstract] [Full Text] [Related]
37. A novel antidiabetic drug, troglitazone--reason for hope and concern.
Imura H
N Engl J Med; 1998 Mar; 338(13):908-9. PubMed ID: 9516229
[No Abstract] [Full Text] [Related]
38. Rapid-onset subfulminant liver failure associated with troglitazone.
Jagannath S; Rai R
Ann Intern Med; 2000 Apr; 132(8):677. PubMed ID: 10766693
[No Abstract] [Full Text] [Related]
39. Effects of pioglitazone on diabetes-related outcomes in Hispanic patients.
Jun JK; Gong WC; Mathur R
Am J Health Syst Pharm; 2003 Mar; 60(5):469-73. PubMed ID: 12635453
[No Abstract] [Full Text] [Related]
40. Pioglitazone and rosiglitazone for diabetes.
Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
